Reviewer’s report

Title: Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events. Results of a long-term follow-up study in routine clinical care

Version: 2 Date: 14 April 2013

Reviewer: Betti Giusti

Reviewer’s report:

Major Compulsory Revisions

The Authors addressed some of the issues raised by this reviewer in a superficial manner

[e.g. discussion of the association of the CYP2C19*2 polymorphism homozygous genotype itself with adverse outcome in patients not taking dual-platelet therapy; improvement in the introduction of the needed background (the Authors should at least mention and report the strong results of the collaborative meta-analysis of Mega and coworkers JAMA 2010 concerning the clinical setting of acute coronary syndrome undergoing percutaneous coronary intervention with stent implantation on clopidogrel therapy); in discussion, what is the new message and what adds their paper with respect to already published data; the Authors should improve the style of the writing]

Minor Essential Revisions

Abstract: Change “CYP2C19*2 polymorphisms are” with “CYP2C19*2 polymorphism is”

Abstract: Add the full stop at the end of the sentence “In n=1050 patients with stable CHD at baseline genotyping of CYP2C19 allele *2 (rs4244285; 681G>A) was performed”

Introduction: Change “p450 cytochrome” with “P450 cytochrome”

Introduction: Remove the full stop: “. Current evidence”

Methods: correct brackets “(rs4244285 (*2(681G>A)”

Results: change “all auf Caucasian origin” with “all of Caucasian origin”

There are several further errors.

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests